Investigating the influence of anti-seizure medications on aperiodic EEG activity.

Clin NeurophysiolSep 3, 2026 (epub)
Clinical ResearchNeurology

Marissa M Holden, Isabella Premoli, Scott R Clark et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial investigated the effects of lamotrigine and levetiracetam on aperiodic EEG activity in 13 healthy male volunteers. Lamotrigine significantly reduced both aperiodic offset and exponent in the eyes-open condition compared to placebo, while levetiracetam only reduced the exponent. These findings suggest distinct pharmacological effects on EEG activity.

Key findings

  • Lamotrigine reduced aperiodic offset and exponent in the eyes-open condition compared to placebo.
  • Levetiracetam reduced the aperiodic exponent without significantly altering the offset.
  • Lamotrigine decreased corrected theta power in both conditions and alpha power during eyes-open.
  • Levetiracetam increased beta power in both conditions and reduced gamma power during eyes-closed.

Why it matters

Understanding how anti-seizure medications influence EEG activity can enhance the interpretation of neurophysiological data and inform treatment strategies for epilepsy and related disorders.

Source

PubMed · PMID 42731196

Published in Clin Neurophysiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.